Therapeutical evaluation of bevacizumab application in relapsed pterygium
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista Brasileira de Oftalmologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802017000500232 |
Resumo: | Abstract Objective: Therapeutic evaluation of Bevacizumab application in relapsed pterygium concerning visual acuity, keratometry, refraction, symptomatology. Methods: Group 1 (4 patients) received 0.1 ml of Bevacizumab (avastin), being evaluated posteriorly on the tenth and thirtieth days after the application, seeking to compare with the exam previously made, being it realized with the other two groups, in which Group 2 (4 patients) received 0.2 ml of Bevacizumab and the Group 3 (3 patients) received 1 ml of the placebo injection. Results: In this study, eleven eyes of eleven patients were evaluated. Among these patients, 7 were women (63.6%) and 4 men (36.4%). There was a variation in the cylindrical diopter after the treatment with a dose of 0.1 ml of bevaciumab during the evaluation on the thirtieth day. Whereas the cylindrical shaft had a significantly larger modification after the application of 0.2 ml. Regarding the spherical diopter variation, there were modifications in the 3 groups. The keratometry varied in the 3 groups, mostly after the thirtieth day of evaluation. In relation to symptomatology, it was observed a reduction in the subjective evaluation of the eye burning sensation, the prurience mentioned by the patient and a reduction of the hyperemia biomicroscopy evaluation. Conclusion: In bevacizumab application in the recurrent pterygium treatment, there is modification of the spherical and cylindrical parameters of refraction, besides the changes in keratometry and the reduction of the symptomatology. |
id |
SBO-1_6cdbee4a1eb5e4f7ce4f77740f16d484 |
---|---|
oai_identifier_str |
oai:scielo:S0034-72802017000500232 |
network_acronym_str |
SBO-1 |
network_name_str |
Revista Brasileira de Oftalmologia (Online) |
repository_id_str |
|
spelling |
Therapeutical evaluation of bevacizumab application in relapsed pterygiumPterygium/drug therapyBevacizumab/therapeutic useVisual acuityRefractionAbstract Objective: Therapeutic evaluation of Bevacizumab application in relapsed pterygium concerning visual acuity, keratometry, refraction, symptomatology. Methods: Group 1 (4 patients) received 0.1 ml of Bevacizumab (avastin), being evaluated posteriorly on the tenth and thirtieth days after the application, seeking to compare with the exam previously made, being it realized with the other two groups, in which Group 2 (4 patients) received 0.2 ml of Bevacizumab and the Group 3 (3 patients) received 1 ml of the placebo injection. Results: In this study, eleven eyes of eleven patients were evaluated. Among these patients, 7 were women (63.6%) and 4 men (36.4%). There was a variation in the cylindrical diopter after the treatment with a dose of 0.1 ml of bevaciumab during the evaluation on the thirtieth day. Whereas the cylindrical shaft had a significantly larger modification after the application of 0.2 ml. Regarding the spherical diopter variation, there were modifications in the 3 groups. The keratometry varied in the 3 groups, mostly after the thirtieth day of evaluation. In relation to symptomatology, it was observed a reduction in the subjective evaluation of the eye burning sensation, the prurience mentioned by the patient and a reduction of the hyperemia biomicroscopy evaluation. Conclusion: In bevacizumab application in the recurrent pterygium treatment, there is modification of the spherical and cylindrical parameters of refraction, besides the changes in keratometry and the reduction of the symptomatology.Sociedade Brasileira de Oftalmologia2017-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802017000500232Revista Brasileira de Oftalmologia v.76 n.5 2017reponame:Revista Brasileira de Oftalmologia (Online)instname:Sociedade Brasileira de Oftalmologia (SBO)instacron:SBO10.5935/0034-7280.20170048info:eu-repo/semantics/openAccessAbrahão,Mayara MartinsTeixeira,Leonardo PinheiroMendanha,Denise Borges de AndradeCampos,Luana MirandaVilar,Mateus Martins CortezNassaralla Junior,João Jorgeeng2018-02-20T00:00:00Zoai:scielo:S0034-72802017000500232Revistahttps://rbo.emnuvens.com.br/rbo/indexhttps://old.scielo.br/oai/scielo-oai.phpsob@sboportal.org.br||rbo@sboportal.org.br1982-85510034-7280opendoar:2018-02-20T00:00Revista Brasileira de Oftalmologia (Online) - Sociedade Brasileira de Oftalmologia (SBO)false |
dc.title.none.fl_str_mv |
Therapeutical evaluation of bevacizumab application in relapsed pterygium |
title |
Therapeutical evaluation of bevacizumab application in relapsed pterygium |
spellingShingle |
Therapeutical evaluation of bevacizumab application in relapsed pterygium Abrahão,Mayara Martins Pterygium/drug therapy Bevacizumab/therapeutic use Visual acuity Refraction |
title_short |
Therapeutical evaluation of bevacizumab application in relapsed pterygium |
title_full |
Therapeutical evaluation of bevacizumab application in relapsed pterygium |
title_fullStr |
Therapeutical evaluation of bevacizumab application in relapsed pterygium |
title_full_unstemmed |
Therapeutical evaluation of bevacizumab application in relapsed pterygium |
title_sort |
Therapeutical evaluation of bevacizumab application in relapsed pterygium |
author |
Abrahão,Mayara Martins |
author_facet |
Abrahão,Mayara Martins Teixeira,Leonardo Pinheiro Mendanha,Denise Borges de Andrade Campos,Luana Miranda Vilar,Mateus Martins Cortez Nassaralla Junior,João Jorge |
author_role |
author |
author2 |
Teixeira,Leonardo Pinheiro Mendanha,Denise Borges de Andrade Campos,Luana Miranda Vilar,Mateus Martins Cortez Nassaralla Junior,João Jorge |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Abrahão,Mayara Martins Teixeira,Leonardo Pinheiro Mendanha,Denise Borges de Andrade Campos,Luana Miranda Vilar,Mateus Martins Cortez Nassaralla Junior,João Jorge |
dc.subject.por.fl_str_mv |
Pterygium/drug therapy Bevacizumab/therapeutic use Visual acuity Refraction |
topic |
Pterygium/drug therapy Bevacizumab/therapeutic use Visual acuity Refraction |
description |
Abstract Objective: Therapeutic evaluation of Bevacizumab application in relapsed pterygium concerning visual acuity, keratometry, refraction, symptomatology. Methods: Group 1 (4 patients) received 0.1 ml of Bevacizumab (avastin), being evaluated posteriorly on the tenth and thirtieth days after the application, seeking to compare with the exam previously made, being it realized with the other two groups, in which Group 2 (4 patients) received 0.2 ml of Bevacizumab and the Group 3 (3 patients) received 1 ml of the placebo injection. Results: In this study, eleven eyes of eleven patients were evaluated. Among these patients, 7 were women (63.6%) and 4 men (36.4%). There was a variation in the cylindrical diopter after the treatment with a dose of 0.1 ml of bevaciumab during the evaluation on the thirtieth day. Whereas the cylindrical shaft had a significantly larger modification after the application of 0.2 ml. Regarding the spherical diopter variation, there were modifications in the 3 groups. The keratometry varied in the 3 groups, mostly after the thirtieth day of evaluation. In relation to symptomatology, it was observed a reduction in the subjective evaluation of the eye burning sensation, the prurience mentioned by the patient and a reduction of the hyperemia biomicroscopy evaluation. Conclusion: In bevacizumab application in the recurrent pterygium treatment, there is modification of the spherical and cylindrical parameters of refraction, besides the changes in keratometry and the reduction of the symptomatology. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802017000500232 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802017000500232 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.5935/0034-7280.20170048 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Oftalmologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Oftalmologia |
dc.source.none.fl_str_mv |
Revista Brasileira de Oftalmologia v.76 n.5 2017 reponame:Revista Brasileira de Oftalmologia (Online) instname:Sociedade Brasileira de Oftalmologia (SBO) instacron:SBO |
instname_str |
Sociedade Brasileira de Oftalmologia (SBO) |
instacron_str |
SBO |
institution |
SBO |
reponame_str |
Revista Brasileira de Oftalmologia (Online) |
collection |
Revista Brasileira de Oftalmologia (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Oftalmologia (Online) - Sociedade Brasileira de Oftalmologia (SBO) |
repository.mail.fl_str_mv |
sob@sboportal.org.br||rbo@sboportal.org.br |
_version_ |
1752122338172731392 |